Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells.

Peters HL, Yan Y, Solheim JC.

Oncoimmunology. 2013 Oct 1;2(10):e26293. Epub 2013 Oct 8.

2.

Specificity of amyloid precursor-like protein 2 interactions with MHC class I molecules.

Tuli A, Sharma M, Naslavsky N, Caplan S, Solheim JC.

Immunogenetics. 2008 Jun;60(6):303-13. doi: 10.1007/s00251-008-0296-0. Epub 2008 May 2.

3.

Amyloid precursor-like protein 2 association with HLA class I molecules.

Tuli A, Sharma M, Wang X, Simone LC, Capek HL, Cate S, Hildebrand WH, Naslavsky N, Caplan S, Solheim JC.

Cancer Immunol Immunother. 2009 Sep;58(9):1419-31. doi: 10.1007/s00262-009-0657-z. Epub 2009 Jan 31. Erratum in: Cancer Immunol Immunother. 2010 Feb;59(2):339.

4.

GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.

Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL.

Oncogene. 2009 Nov 19;28(46):4126-32. doi: 10.1038/onc.2009.262. Epub 2009 Aug 31.

PMID:
19718047
5.

Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells.

Peters HL, Yan Y, Nordgren TM, Cutucache CE, Joshi SS, Solheim JC.

Cancer Biol Ther. 2013 Aug;14(8):752-60. doi: 10.4161/cbt.25183. Epub 2013 Jun 26.

6.

Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.

Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska-Kwiatkowska A, Blackburn M, Chansky K, Conrad EU 3rd, Bruckner JD, Greenlee TK, Yang L.

J Orthop Res. 2004 Jul;22(4):910-7.

7.

Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.

Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL, Nakatani F, Scotlandi K, Reiter M, Strunk D, Speleman F, Vandesompele J, Kovar H.

Oncogene. 2011 May 5;30(18):2173-80. doi: 10.1038/onc.2010.581. Epub 2011 Jan 10.

8.

NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.

Kinsey M, Smith R, Lessnick SL.

Mol Cancer Res. 2006 Nov;4(11):851-9.

9.

A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.

Girnita L, Girnita A, Wang M, Meis-Kindblom JM, Kindblom LG, Larsson O.

Oncogene. 2000 Aug 31;19(37):4298-301.

10.

EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.

Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G, Saitou M, Takigami I, Matsuhashi A, Yamada K, Takei Y.

Int J Cancer. 2010 Jun 15;126(12):2790-8. doi: 10.1002/ijc.24781.

11.

High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM.

PLoS One. 2010 Nov 11;5(11):e13943. doi: 10.1371/journal.pone.0013943.

12.

EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.

Owen LA, Kowalewski AA, Lessnick SL.

PLoS One. 2008 Apr 16;3(4):e1965. doi: 10.1371/journal.pone.0001965.

13.

Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.

Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES.

Oncogene. 1995 Sep 21;11(6):1049-54.

PMID:
7566963
15.

DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.

García-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gómez-López G, Pestaña A, Alonso J.

Oncogene. 2008 Oct 9;27(46):6034-43. doi: 10.1038/onc.2008.203. Epub 2008 Jun 30.

PMID:
18591936
16.

Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.

Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M.

Cancer Res. 1999 Apr 1;59(7):1428-32.

17.

Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.

Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AH, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJ, Egeler RM, Schilham MW, Jordanova ES, Hogendoorn PC, Lankester AC.

J Pathol. 2009 Jun;218(2):222-31. doi: 10.1002/path.2537.

PMID:
19274709
18.

EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model.

Peng W, Huang X, Yang D.

Int Immunopharmacol. 2014 Aug;21(2):336-41. doi: 10.1016/j.intimp.2014.05.013. Epub 2014 May 24.

PMID:
24861249
19.

FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.

Yang L, Hu HM, Zielinska-Kwiatkowska A, Chansky HA.

Biochem Biophys Res Commun. 2010 Nov 5;402(1):129-34. doi: 10.1016/j.bbrc.2010.09.129. Epub 2010 Oct 8.

20.

Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation.

Tuli A, Sharma M, Capek HL, Naslavsky N, Caplan S, Solheim JC.

J Biol Chem. 2009 Dec 4;284(49):34296-307. doi: 10.1074/jbc.M109.039727. Epub 2009 Oct 6.

Supplemental Content

Support Center